HealthQuartzabout 1 hour ago
AstraZeneca Pays Insitro $40 Million for AI Targets
2 min read
AstraZeneca announced a collaboration with AI company insitro on Thursday, paying $40 million upfront to identify drug targets for liver and heart diseases. The deal includes potential milestones totaling roughly $1.46 billion, leveraging insitro's Virtual Human AI platform to address complex conditions where AstraZeneca recently failed.
Level
Hype check
Tap to vote and see what everyone thinks.
